We are live on
!
Find out more
ABI
Adamant Biomedical Investments Portfolio holdings
AUM
$418M
This Fund
S&P 500
This Quarter
Est. Return
+5.6%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$401M
AUM Growth
–
Cap. Flow
+$398M
Cap. Flow
% of AUM
99.27%
Top 10 Holdings %
Top 10 Hldgs %
34.69%
Holding
96
New
96
Increased
–
Reduced
–
Closed
–
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$19.2M |
| 2 |
CELG
Celgene Corp
CELG
|
+$18.7M |
| 3 |
Biogen
BIIB
|
+$18.1M |
| 4 |
CYTO
Altamira Therapeutics Ltd
CYTO
|
+$13.4M |
| 5 |
Amgen
AMGN
|
+$13.1M |
Top Sells
No sells this quarter
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 86.61% |
| 2 | Financials | 1.21% |
| 3 | Industrials | 0.33% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
COV
26
DELISTED
COVIDIEN PLC COM SHS NEW (IRELAND)
COV
| $5.19M | 1.3% |
+60,000
| New | +$5.31M |
|
|
QGENF
27
DELISTED
QIAGEN NV
QGENF
| $5.19M | 1.3% |
+250,610
| New | +$5.19M |
|
28
Eli Lilly
LLY
$1.06T
| $5.19M | 1.29% |
+80,000
| New | +$5.07M |
|
|
AET
29
DELISTED
Aetna Inc
AET
| $4.86M | 1.21% |
+60,000
| New | +$4.88M |
|
30
Johnson & Johnson
JNJ
$625B
| $4.8M | 1.2% |
+45,000
| New | +$4.67M |
|
31
Baxter International
BAX
$14.2B
| $4.67M | 1.16% |
+119,665
| New | +$4.86M |
|
32
Stryker
SYK
$130B
| $4.64M | 1.16% |
+57,500
| New | +$4.73M |
|
33
Humana
HUM
$46.2B
| $4.56M | 1.14% |
+35,000
| New | +$4.45M |
|
34
Elevance Health
ELV
$85.5B
| $4.55M | 1.13% |
+38,000
| New | +$4.36M |
|
35
Cigna
CI
$74.6B
| $4.54M | 1.13% |
+50,000
| New | +$4.67M |
|
36
Brookdale Senior Living
BKD
$3.4B
| $4.43M | 1.11% |
+137,620
| New | +$4.69M |
|
37
Dr. Reddy's Laboratories
RDY
$10.2B
| $4.2M | 1.05% |
+400,000
| New | +$3.76M |
|
38
Perrigo
PRGO
$1.78B
| $4.15M | 1.04% |
+30,750
| New | +$4.59M |
|
|
ESRX
39
DELISTED
Express Scripts Holding Company
ESRX
| $4.03M | 1% |
+57,000
| New | +$4.06M |
|
|
STJ
40
DELISTED
St Jude Medical
STJ
| $3.91M | 0.98% |
+65,000
| New | +$4.25M |
|
|
LCI
41
DELISTED
Lannett Company, Inc.
LCI
| $3.65M | 0.91% |
+20,000
| New | +$3.2M |
|
42
BioMarin Pharmaceuticals
BMRN
$12.4B
| $3.61M | 0.9% |
+50,000
| New | +$3.29M |
|
43
CVS Health
CVS
$122B
| $3.58M | 0.89% |
+45,000
| New | +$3.55M |
|
44
Incyte
INCY
$24.4B
| $3.43M | 0.86% |
+70,000
| New | +$3.51M |
|
45
Jazz Pharmaceuticals
JAZZ
$16.7B
| $3.21M | 0.8% |
+20,000
| New | +$3.07M |
|
46
HCA Healthcare
HCA
$89.5B
| $3.17M | 0.79% |
+45,000
| New | +$2.97M |
|
47
Insulet
PODD
$9.79B
| $2.95M | 0.74% |
+80,000
| New | +$2.92M |
|
48
ResMed
RMD
$30.7B
| $2.93M | 0.73% |
+59,450
| New | +$3.03M |
|
|
SHPG
49
DELISTED
Shire pic
SHPG
| $2.85M | 0.71% |
+11,000
| New | +$2.73M |
|
|
ENDP
50
DELISTED
Endo International plc
ENDP
| $2.73M | 0.68% |
+40,000
| New | +$2.63M |
|
Similar funds
AGCJ
ACM
RNS
NTP
MMC
LOM
CAMI
NES
Adamant Biomedical Investments's Q3 2014 Portfolio in Review
Q3 2014 is the first quarter with a 13F filing on record for Adamant Biomedical Investments, which disclosed 96 positions worth $401M. Its ten largest holdings account for 35% of the portfolio.
Its largest position is Gilead Sciences: 196,390 shares worth $20.9M.
By sector, the portfolio is most concentrated in Healthcare at 87% of assets, followed by Financials and Industrials.
- Adamant Biomedical Investments's largest Q3 2014 buy was Gilead Sciences: 196,390 shares worth $20.9M.
- Adamant Biomedical Investments's ten largest holdings make up 35% of its $401M portfolio in Q3 2014.
- Adamant Biomedical Investments disclosed 96 positions in Q3 2014, its first 13F filing on record.
Based on Adamant Biomedical Investments's 13F filing for Q3 2014, filed 14 Nov 2014.